| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | B3GNT7 |
| Uniprot No | Q8NFL0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-401aa |
| 氨基酸序列 | RSLTPGQFLQEPPPPTLEPQKAQKPNGQLVNPNNFWKNPKDVAAPTPMASQGPQAWDVTTTNCSANINLTHQPWFQVLEPQFRQFLFYRHCRYFPMLLNHPEKCRGDVYLLVVVKSVITQHDRREAIRQTWGRERQSAGGGRGAVRTLFLLGTASKQEERTHYQQLLAYEDRLYGDILQWGFLDTFFNLTLKEIHFLKWLDIYCPHVPFIFKGDDDVFVNPTNLLEFLADRQPQENLFVGDVLQHARPIRRKDNKYYIPGALYGKASYPPYAGGGGFLMAGSLARRLHHACDTLELYPIDDVFLGMCLEVLGVQPTAHEGFKTFGISRNRNSRMNKEPCFFRAMLVVHKLLPPELLAMWGLVHSNLTCSRKLQVL |
| 预测分子量 | 50.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于B3GNT7重组蛋白的参考文献及其摘要概括：
1. **文献名称**: "Cloning and Characterization of Human β3Gn-T7. a Novel Member of the β3-Gn-T Family"
**作者**: Ishida H, et al.
**摘要**: 该研究首次克隆并表征了人源B3GNT7基因，证明其编码的蛋白属于β3-GlcNAc转移酶家族。通过体外重组表达，发现B3GNT7特异性催化聚乳糖胺链的合成，参与特定糖基化修饰过程。
2. **文献名称**: "B3GNT7 regulates mucin biosynthesis in colon cancer cells via core 3 O-glycan formation"
**作者**: Iwai T, et al.
**摘要**: 研究利用重组B3GNT7蛋白，揭示了其在结肠癌细胞中通过合成核心3 O-聚糖调控黏蛋白生物合成的机制，表明其表达缺失可能与癌症进展相关。
3. **文献名称**: "Enzymatic Properties of Recombinant Human β3Gn-T7 Expressed in Insect Cells"
**作者**: Seko A, et al.
**摘要**: 通过在昆虫细胞系统中重组表达B3GNT7.分析了其酶动力学特性，证实其对β1.3-糖苷键合成的底物特异性，并探讨了金属离子对酶活性的影响。
4. **文献名称**: "B3GNT7 promotes tumor metastasis through enhancing EGFR/ERK signaling in lung adenocarcinoma"
**作者**: Chen Y, et al.
**摘要**: 研究利用重组B3GNT7蛋白及基因敲除模型，证明其通过介导EGFR糖基化增强ERK信号通路，从而促进肺腺癌转移，为靶向治疗提供潜在靶点。
注：以上文献为示例，实际引用时需根据具体研究内容核对原文。
**Background of B3GNT7 Recombinant Protein**
B3GNT7 (β-1.3-N-acetylglucosaminyltransferase 7) is a key enzyme in glycosylation, a post-translational modification critical for protein folding, cell signaling, and intercellular interactions. It belongs to the β3GlcNAcT family and catalyzes the transfer of N-acetylglucosamine (GlcNAc) to galactose-containing glycans via a β-1.3 linkage. This activity contributes to the biosynthesis of linear poly-N-acetyllactosamine chains, core structures in O-glycans, and glycosphingolipids, which are essential for cellular adhesion, immune responses, and pathogen recognition.
B3GNT7 is notably involved in synthesizing mucin-type glycans, heavily expressed in epithelial tissues. Dysregulation of B3GNT7 has been linked to pathologies, including cancer metastasis, inflammation, and autoimmune diseases. For instance, its overexpression in certain cancers promotes tumor cell invasion by altering glycan profiles on cell surfaces, facilitating interactions with selectins or galectins during metastasis.
Recombinant B3GNT7 protein is engineered for in vitro studies to dissect its enzymatic mechanisms, substrate specificity, and role in disease. Produced using expression systems like mammalian cells or bacteria, the purified protein retains catalytic activity and is utilized in functional assays, inhibitor screening, and structural studies. Researchers also employ it to generate antibodies or model glycan biosynthesis pathways.
Current research focuses on targeting B3GNT7 for therapeutic interventions, particularly in cancers where aberrant glycosylation drives malignancy. Understanding its regulation and interactions may unveil biomarkers or drug candidates to modulate glycan-mediated processes in disease contexts.
×
